FDA clears Baxter’s prepackaged synthetic bone filler graft

Baxter International received an FDA clearance for a new formulation of its Actifuse synthetic bone graft substitute, now deliverable via a prepackaged syringe that requires no mixing or preparation.
For use in a variety of orthopedic surgeries, Actifuse Flow uses the same silicate-substitution technology to help accelerate bone formation after being placed in small voids or gaps in the skeletal system.
The latest addition to Baxter’s osteobiologics portfolio, it is designed to maintain a flowable consistency throughout surgery. As the graft is resorbed, it is replaced by the patient’s own bone during the healing process.